Beneficial effects of angiotensin II type 1 receptor blocker antihypertensive treatment on inflammation indices: the effect of smoking.
The effect of long-term angiotensin II type 1 receptor blocker (ARB) therapy on inflammation indices has not been fully investigated in a hypertensive population. The authors evaluated 323 consecutive nondiabetic patients (mean age, 57 years; 176 men; 92 smokers) with high renin activity and uncomplicated essential hypertension whose blood pressure levels normalized (from 163.9/100.7 mm Hg to 131.6/82.8 mm Hg) after 4 weeks of ARB or ARB/diuretic treatment. All patients underwent full laboratory evaluation (routine examination of blood and urine, liver, kidney, thyroid function, and lipid and glucose profiles), including measurement of high-sensitivity C-reactive protein and serum amyloid A levels, at drug-free baseline, which was repeated after 6 months of ARB or ARB/diuretic treatment. A significant (P<.001) overall decrease was noted in both high-sensitivity C-reactive protein (-0.41+/-1.56 mg/dL) and serum amyloid A (-0.62+/-2.03 mg/dL), but a smaller decrease in high-sensitivity C-reactive protein and serum amyloid A change was seen in the smoker subgroup compared with nonsmokers (P<.05), indicating that the ARB or ARB/diuretic anti-inflammatory effect may be adversely affected by smoking status.
Kyvelou
Stella-Maria G
SM
Hypertension Unit, First Cardiology Department, Athens Medical School, Hippokration Hospital, First Cardiology Department of Onassis Cardiosurgery Center, Athens, Greece. kyvelou113@yahoo.gr
Vyssoulis
Gregory P
GP
Karpanou
Eva A
EA
Adamopoulos
Dionysios N
DN
Gialernios
Theodoros P
TP
Pietri
Panagiota G
PG
Cokkinos
Dennis V
DV
Stefanadis
Christodoulos I
CI
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D002097:C-Reactive Protein / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D007249:Inflammation / Q000097:blood* / Q000150:complications; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D000685:Serum Amyloid A Protein / Q000187:drug effects / Q000378:metabolism*; D012907:Smoking / Q000009:adverse effects*; D016896:Treatment Outcome
D047228:Angiotensin II Type 1 Receptor Blockers; D015415:Biomarkers; D000685:Serum Amyloid A Protein; D002097:C-Reactive Protein